- Home
- KYTX
as 11-21-2024 4:00pm EST
Stocks
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 242.1M | IPO Year: | 2024 |
| Target Price: | $23.20 | AVG Volume (30 days): | 248.8K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.94 - $30.60 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest KYVERNA THERAPEUTICS INC News
KYTX Breaking Stock News: Dive into KYTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop
PR Newswire
7 days ago
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
PR Newswire
8 days ago
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
PR Newswire
a month ago
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
Insider Monkey
a month ago
Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy
GuruFocus.com
a month ago
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc
MT Newswires
a month ago
UBS Initiates Kyverna Therapeutics at Buy With $13 Price Target
PR Newswire
2 months ago
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
Compare KYTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KYTX KYVERNA THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.